{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:47:18Z","timestamp":1782247638125,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"DOI":"10.7759\/cureus.111377","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T19:48:06Z","timestamp":1782244086000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological Management of Secondary Hyperparathyroidism in Dialysis Patients: A Narrative Review of Calcimimetics, Vitamin D Analogs, and Phosphate Binders"],"prefix":"10.7759","author":[{"given":"Hanin","family":"Alwashahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanalekshmi","family":"Unnikrishnan Meenakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","unstructured":"Global, regional, and national burden of chronic kidney disease, 1990-2017. a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020, 395:709-33. 10.1016\/S0140-6736(20)30045-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh J","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA, et al.. Prevalence of chronic kidney disease in the United States. JAMA. 2007, 298:2038-47. 10.1001\/jama.298.17.2038","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block GA","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004, 15:2208-18. 10.1097\/01.ASN.0000133041.27682.A2","journal-title":"J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118701","article-title":"Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro","volume":"97","author":"Slatopolsky E","year":"1996","unstructured":"Slatopolsky E, Finch J, Denda M, et al.. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest. 1996, 97:2534-40. 10.1172\/JCI118701","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone\u00a0Disorder (CKD-MBD)","volume":"7","year":"2017","unstructured":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone\u00a0Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017, 7.1-59. 10.1016\/j.kisu.2017.04.001","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000772020","article-title":"Parathyroid Hormone Serum Levels and Mortality among Hemodialysis Patients in the Gulf Cooperation Council Countries: Results from the DOPPS (2012-2018)","volume":"1","author":"Al Salmi I","year":"2020","unstructured":"Al Salmi I, Bieber B, Al Rukhaimi M, et al.. Parathyroid Hormone Serum Levels and Mortality among Hemodialysis Patients in the Gulf Cooperation Council Countries: Results from the DOPPS (2012-2018). Kidney360. 2020, 1:1083-90. 10.34067\/KID.0000772020","journal-title":"Kidney360"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori F","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM, et al.. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008, 52:519-30. 10.1053\/j.ajkd.2008.03.020","journal-title":"Am J Kidney Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.12.003","article-title":"Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy","volume":"43","author":"Martin KJ","year":"2004","unstructured":"Martin KJ, Olgaard K, Coburn JW, et al.. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004, 43:558-65. 10.1053\/j.ajkd.2003.12.003","journal-title":"Am J Kidney Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005111194","article-title":"Relationship between moderate to severe kidney disease and hip fracture in the United States","volume":"17","author":"Nickolas TL","year":"2006","unstructured":"Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006, 17:3223-32. 10.1681\/ASN.2005111194","journal-title":"J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh SK","year":"2001","unstructured":"Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001, 12:2131-8. 10.1681\/ASN.V12102131","journal-title":"J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono S","year":"2000","unstructured":"Jono S, McKee MD, Murry CE, et al.. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000, 87:E10-7. 10.1161\/01.res.87.7.e10","journal-title":"Circ Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.26719\/2011.17.4.317","article-title":"High prevalence of vitamin D deficiency in the sunny Eastern region of Saudi Arabia: a hospital-based study","volume":"17","author":"Elsammak MY","year":"2011","unstructured":"Elsammak MY, Al-Wossaibi AA, Al-Howeish A, Alsaeed J. High prevalence of vitamin D deficiency in the sunny Eastern region of Saudi Arabia: a hospital-based study. East Mediterr Health J. 2011, 17:317-22. 10.26719\/2011.17.4.317","journal-title":"East Mediterr Health J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-020-00655-9","article-title":"Prevalence and risk factors of diabetes in a large community-based study in the Sultanate of Oman: STEPS survey 2017","volume":"21","author":"Al-Mawali A","year":"2021","unstructured":"Al-Mawali A, Al-Harrasi A, Jayapal SK, et al.. Prevalence and risk factors of diabetes in a large community-based study in the Sultanate of Oman: STEPS survey 2017. BMC Endocr Disord. 2021, 21:42. 10.1186\/s12902-020-00655-9","journal-title":"BMC Endocr Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6403985","article-title":"End-stage kidney failure in Oman: an analysis of registry data with an emphasis on congenital and inherited renal diseases","volume":"2017","author":"Al Alawi I","year":"2017","unstructured":"Al Alawi I, Al Salmi I, Al Mawali A, Al Maimani Y, Sayer JA. End-stage kidney failure in Oman: an analysis of registry data with an emphasis on congenital and inherited renal diseases. Int J Nephrol. 2017, 2017:6403985. 10.1155\/2017\/6403985","journal-title":"Int J Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow GM","year":"2002","unstructured":"Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002, 62:245-52. 10.1046\/j.1523-1755.2002.00434.x","journal-title":"Kidney Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block GA","year":"2005","unstructured":"Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005, 68:1815-24. 10.1111\/j.1523-1755.2005.00600.x","journal-title":"Kidney Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague SM","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003, 63:1483-90. 10.1046\/j.1523-1755.2003.00878.x","journal-title":"Kidney Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block GA","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, et al.. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004, 350:1516-25. 10.1056\/NEJMoa031633","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow GM","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, et al.. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012, 367:2482-94. 10.1056\/NEJMoa1205624","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-9-2","article-title":"A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease","volume":"9","author":"Karamanidou C","year":"2008","unstructured":"Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008, 9:2. 10.1186\/1471-2369-9-2","journal-title":"BMC Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova T","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, et al.. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011, 79:1370-8. 10.1038\/ki.2011.47","journal-title":"Kidney Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng M","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003, 349:446-56. 10.1056\/NEJMoa022536","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493776-pharmacological-management-of-secondary-hyperparathyroidism-in-dialysis-patients-a-narrative-review-of-calcimimetics-vitamin-d-analogs-and-phosphate-binders","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T19:48:07Z","timestamp":1782244087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493776-pharmacological-management-of-secondary-hyperparathyroidism-in-dialysis-patients-a-narrative-review-of-calcimimetics-vitamin-d-analogs-and-phosphate-binders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.111377","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}